Last Updated:
10 Mar 2026, 03:30:03 PM (IST)
Syncom Formulations (India) Limited
NSE: SYNCOMF BSE: SYNCOMF
NSE
12.23
0.33 (2.77%)
Prev Close
11.9
Open Price
12.17
Volume
1,209,776
Today Low / High
11.88 / 12.6
52 WK Low / High
11.53 / 23.49
Range
12 - 13
BSE
12.27
0.41 (3.46%)
Prev Close
11.86
Open Price
12.1
Volume
86,515
Today Low / High
11.93 / 12.3
52 WK Low / High
11.36 / 23.46
Range
12 - 13
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 12.23 (target range: 12 - 13), reflecting a change of 0.33 (2.77311%). On the BSE, it is listed at 12.27 (target range: 12 - 13), showing a change of 0.41 (3.457%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Syncom Formulations (India) Limited Graph
Syncom Formulations (India) Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Syncom Formulations (India) Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 12.23, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 12.27 | 12.39 | 11.15 - 13.63 |
| 12.52 | 10.01 - 15.02 | ||
| 12.64 | 8.85 - 16.43 | ||
| Bearish Scenario | 12.27 | 12.15 | 10.93 - 13.36 |
| 12.02 | 9.62 - 14.43 | ||
| 11.90 | 8.33 - 15.47 |
Overview of Syncom Formulations (India) Limited
ISIN
INE312C01025
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,507,294
Market Cap
11,571,400,000
Last Dividend
0
Official Website
IPO Date
2022-11-18
DCF Diff
16.34
DCF
-4
Financial Ratios Every Investor Needs
Stock Dividend of SYNCOMF
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-09 | September 09, 22 | 0.03 | 0.03 | 2022-09-12 | 2022-10-19 | |
| 2017-09-21 | September 21, 17 | 0.02 | 0.02 | 2017-09-22 | 2017-10-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 465.01 Cr | 307.34 Cr | 157.68 Cr | 0.3391 | 0.00 Cr | 53.53 Cr | 48.94 Cr | 49.43 Cr | 0.57 | 71.17 Cr | 0.1063 |
| 2024-03-31 | 263.39 Cr | 156.88 Cr | 55.95 Cr | 0.2124 | 0.00 Cr | 2.20 Cr | 21.39 Cr | 25.31 Cr | 0.27 | 43.03 Cr | 0.0961 |
| 2023-03-31 | 224.25 Cr | 141.70 Cr | 82.56 Cr | 0.3681 | 0.00 Cr | 2.62 Cr | 15.22 Cr | 20.07 Cr | 0.22 | 34.15 Cr | 0.0895 |
| 2022-03-31 | 217.82 Cr | 146.85 Cr | 70.97 Cr | 0.3258 | 0.00 Cr | 1.89 Cr | 14.75 Cr | 19.79 Cr | 0.24 | 31.96 Cr | 0.0909 |
| 2021-03-31 | 239.32 Cr | 167.07 Cr | 72.24 Cr | 0.3019 | 0.00 Cr | 1.42 Cr | 28.72 Cr | 29.17 Cr | 0.37 | 45.03 Cr | 0.1219 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.71 Cr | 413.28 Cr | 71.12 Cr | 342.1576 Cr | 4.58 Cr | 3.87 Cr | 41.33 Cr | 77.53 Cr | 0.00 Cr | 0.18 Cr | 16.92 Cr | 59.3107 Cr |
| 2024-03-31 | 63.29 Cr | 404.66 Cr | 117.35 Cr | 288.1428 Cr | 72.49 Cr | 9.19 Cr | 21.08 Cr | 72.31 Cr | 3.55 Cr | 0.12 Cr | 52.26 Cr | 106.5246 Cr |
| 2023-03-31 | 0.88 Cr | 377.83 Cr | 121.82 Cr | 256.0147 Cr | 83.18 Cr | 82.30 Cr | 21.20 Cr | 68.81 Cr | 4.64 Cr | 0.13 Cr | 124.90 Cr | 113.1596 Cr |
| 2022-03-31 | 0.22 Cr | 308.24 Cr | 86.02 Cr | 222.2216 Cr | 57.79 Cr | 57.57 Cr | 19.51 Cr | 52.71 Cr | 1.07 Cr | 0.11 Cr | 65.97 Cr | 78.2557 Cr |
| 2021-03-31 | 2.64 Cr | 291.65 Cr | 104.07 Cr | 187.5840 Cr | 62.09 Cr | 59.45 Cr | 22.56 Cr | 44.58 Cr | 5.30 Cr | 0.18 Cr | 8.82 Cr | 96.7040 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23.4361 Cr | -18.2042 Cr | -67.9033 Cr | 13.4768 Cr | -62.6714 Cr | 0.7120 Cr | -9.9593 Cr | 49.4346 Cr | -67.9030 Cr | 0.0000 Cr | -20.2505 Cr |
| 2024-03-31 | -5.9583 Cr | 83.0196 Cr | -14.5576 Cr | -14.0947 Cr | 62.5037 Cr | 63.3834 Cr | -8.1364 Cr | 25.3142 Cr | -10.6949 Cr | 0.0000 Cr | 0.1188 Cr |
| 2023-03-31 | 10.5293 Cr | -44.9527 Cr | 35.0014 Cr | -10.1054 Cr | 0.5780 Cr | 0.8797 Cr | -20.6347 Cr | 26.5593 Cr | 25.3907 Cr | -2.8200 Cr | -1.6940 Cr |
| 2022-03-31 | 16.3290 Cr | -27.0733 Cr | 8.2945 Cr | 5.0161 Cr | -2.4497 Cr | 0.3017 Cr | -11.3129 Cr | 26.1519 Cr | -4.2993 Cr | 0.0000 Cr | 3.0489 Cr |
| 2021-03-31 | -1.9935 Cr | -75.4625 Cr | 71.9604 Cr | -4.7189 Cr | -5.4561 Cr | 5.4768 Cr | -2.7254 Cr | 40.6739 Cr | 59.9425 Cr | 0.0000 Cr | -6.4829 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 115.14 Cr | 79.85 Cr | 35.29 Cr | 0.3065 | 19.85 Cr | 18.91 Cr | 0.20 | 21.21 Cr | 0.1642 |
| 2025-09-30 | 121.72 Cr | 88.84 Cr | 32.88 Cr | 0.2701 | 17.05 Cr | 16.60 Cr | 0.18 | 23.65 Cr | 0.1364 |
| 2025-06-30 | 116.90 Cr | 69.17 Cr | 47.73 Cr | 0.4083 | 14.47 Cr | 15.75 Cr | 0.21 | 21.88 Cr | 0.1348 |
| 2025-03-31 | 148.88 Cr | 100.37 Cr | 48.51 Cr | 0.3258 | 16.47 Cr | 17.69 Cr | 0.16 | 17.63 Cr | 0.1189 |
| 2024-12-31 | 127.53 Cr | 86.66 Cr | 40.88 Cr | 0.3205 | 13.42 Cr | 13.00 Cr | 0.14 | 18.77 Cr | 0.1019 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.28 Cr | 143.82 Cr | 145.09 Cr | 102.24 Cr | 28.51 Cr | 303.69 Cr | 84.71 Cr | 456.08 Cr | 77.59 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 89.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -342.16 Cr |
| 2025-03-31 | 0.71 Cr | 89.22 Cr | 89.93 Cr | 107.55 Cr | 41.33 Cr | 269.97 Cr | 77.53 Cr | 413.28 Cr | 71.12 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 92.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -313.56 Cr |
| 2024-09-30 | 0.25 Cr | 91.76 Cr | 92.01 Cr | 88.24 Cr | 45.05 Cr | 245.82 Cr | 71.41 Cr | 372.45 Cr | 58.89 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 15.75 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 17.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 13.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 11.11 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 7.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Executive Chairman
Ankit Kedarmal Bankda
Gender: male
Year Born: 1986
President of Export Marketing
Ankur Vijay Bankda
Gender: male
Year Born: 1985
Whole Time Director
Kedarmal Shankarlal Bankda
Gender: male
Year Born: 1952
Chief Financial Officer & President of Domestic Marketing
Rahul Vijay Bankda
Gender: male
Year Born: 1980
Chief Marketing Officer
Rakesh Chandra Srivastava
Gender: male
Year Born: 1962
MD and Executive & Non Independent Director
Vijay Shankarlal Bankda
Gender: male
Year Born: 1958
Vice President of Human Resources
Payal Ankur Bankda
Gender: female
Year Born: 1987
Company Secretary & Compliance Officer
Vaishali Agrawal
Gender: female
Year Born:
FAQs about Syncom Formulations (India) Limited
Who is the CEO of the company?
The CEO is Ankit Kedarmal Bankda.
What is the current market price of the stock?
The current price is ₹12.31.
What is the 52-week price range?
The range is ₹11.53-23.49.
What is the market capitalization of the company?
The market capitalization is ₹1,157.14 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 16.78.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Syncom Formulations (India) Limited (ISIN: INE312C01025) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,157.14 crores and an average daily volume of 1,507,294 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.